Half-Life Determines Everything
In pharmacokinetics, a drug's half-life (denoted as t½) is the fundamental parameter governing its entire dosing protocol. It is defined as the time required for the concentration of the peptide in the blood plasma to decrease by exactly 50%. For example, if a peptide has a half-life of 4 hours, and you inject 1000mcg, your circulating levels will drop to roughly 500mcg after 4 hours, 250mcg after 8 hours, and 125mcg after 12 hours.
This single metric commands how frequently you must inject to maintain stable blood levels. For instance, BPC-157 has a notoriously short half-life of roughly 4 to 6 hours. Therefore, a single daily injection leaves the body essentially devoid of the peptide for over half the day. Conversely, modified GLP-1 agonists like Semaglutide feature a synthetic fatty acid chain that binds to albumin in the blood, drastically extending their half-life to an incredible 168 hours (7 days), enabling a highly convenient once-weekly injection schedule.
The ultimate goal of any administration protocol is to maintain plasma levels strictly within the "therapeutic window." Too infrequent dosing creates deep troughs where the peptide is absent and healing stalls. Too frequent or excessively large dosing wastes product, spikes plasma levels dangerously high, and may cause severe receptor downregulation or tachyphylaxis (rapid desensitization).
The Physiology of Peptide Clearance
Why do most endogenous peptides have such short half-lives? The human body is packed with proteolytic enzymes (proteases and peptidases) whose sole job is to hunt down and cleave protein bonds. Native GLP-1, for instance, is hunted by the DPP-4 enzyme and destroyed in under two minutes. Growth Hormone Releasing Hormone (GHRH) lasts only minutes before being broken down.
To make peptides viable for clinical therapy, scientists use several half-life extension strategies. These include PEGylation (attaching polyethylene glycol chains), lipidation (attaching fatty acids to bind with blood proteins like albumin, as seen in Tirzepatide), and substituting natural L-amino acids with synthetic D-amino acids that human enzymes cannot easily recognize or cleave.
Dosing Frequency Guidelines by Half-Life Tier
Understanding the clearance rate of your specific compound ensures you are neither under-dosing nor over-saturating your receptors. Here are the general rules of thumb based on established half-life tiers:
• Ultra-short half-life (1-2 hours): This category primarily includes Growth Hormone secretagogues like Ipamorelin and GHRP-6. Because they clear so rapidly, they are typically dosed 2 to 3 times daily. Often, they are timed around natural GH pulses, such as immediately pre-sleep and first thing in the morning while in a fasted state.
• Short half-life (2-6 hours): Healing and repair peptides such as BPC-157 and TB-500 fall into this range, alongside nootropics like Selank and Semax. BPC-157 is optimally dosed twice daily (e.g., morning and night) to maintain a steady healing response. TB-500 is historically unique; despite a short half-life, its systemic long-term tissue effects often allow for bi-weekly dosing in practical application.
• Medium half-life (6-24 hours): Melanotan II (MT2), PT-141 (Bremelanotide), and DSIP (Delta Sleep-Inducing Peptide). These are typically dosed on an "as-needed" or once-daily basis. MT2 and PT-141 are dosed a few hours before the desired effect, while DSIP is dosed directly before sleep.
• Long half-life (24 to 72 hours): Compounds like CJC-1295 with DAC (Drug Affinity Complex). The DAC modification binds to blood albumin, stretching the half-life to roughly 6-8 days in humans. This allows for convenient once-weekly or twice-weekly micro-dosing. Caution is advised, as sustained receptor activation without pulsatile breaks can cause GH receptor desensitization.
• Ultra-long half-life (72+ hours): Modern GLP-1/GIP receptor agonists. Semaglutide's 7-day half-life and Tirzepatide's 5-day half-life dictate a strict once-weekly injection protocol. Because it takes approximately 4-5 half-lives for a drug to reach "steady state" concentration in the blood, these medications build up slowly over the first month of use, which is why clinical titration schedules mandate 4 weeks at each dose tier.
